SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ: CYTX) (“Cytori” or the “Company”) today announced that it has received the Frost & Sullivan 2016 Technology Innovation Award in recognition of advancements made in the field of regenerative medicine for over a decade. Frost & Sullivan’s industry research and benchmarking analysis report that Cytori’s pioneering technology platform has become the leading technology to enable the research and practice of cellular therapies that harness the potential of stem and regenerative cells from adipose tissue.
Frost & Sullivan Industry Analyst Cecilia Van Cauwenberghe commented, “Cytori is devoted to the development of cellular therapeutics as its Cell Therapy™ platform exploits the unique attributes of adipose derived stem cells for repair and healing. With a strong intellectual property portfolio of 89 patents, a broad spectrum of pre-clinical and clinical trials, and an extensive network of distribution and commercialization partners, we believe Cytori has become a global leader in the cell therapeutics market. We are pleased to confer this technology innovation award on Cytori Therapeutics.”
“Our team is honored to receive the 2016 technology innovation award,” said Dr. Marc H. Hedrick, President and Chief Executive Officer of Cytori. “Frost & Sullivan is a leader in evaluating markets and forecasting business opportunity and this award is a clear recognition of the hard work and dedication of many - both our employees and the doctors and patients with whom we have worked over the years.”
For more information about Cytori Therapeutics, the Frost & Sullivan 2016 Technology Innovation Award, and the Frost & Sullivan Report Cell Therapeutics - North America Technology Innovation Award on Cytori Therapeutics, please visit www.cytori.com.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages almost 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit www.frost.com.
Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information, visit www.cytori.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, without limitation, statements regarding focused execution of our late stage approval trials and commercialization of cell based therapeutics, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, inherent risk and uncertainty in the protection intellectual property rights, regulatory uncertainties, risks in the conduct of clinical trials, risks in the collection and results of clinical data, final clinical outcomes, dependence on third party performance, performance and acceptance of our products in the marketplace, as well as other risks and uncertainties described under the heading "Risk Factors" in Cytori's Securities and Exchange Commission Filings on Form 10-K and Form 10-Q. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.